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Abstract
Background: Bordetella pertussis is the primary etiologic agent of the disease pertussis. Universal immunization programs
have contributed to a significant reduction in morbidity and mortality of pertussis; however, incidence of the disease,
especially in adolescents and adults, has increased in several countries despite high vaccination coverage. During the last
three decades, strains of Bordetella pertussis in circulation have shifted from the vaccine-type to the nonvaccine-type in
many countries. A comparative proteomic analysis of the strains was performed to identify protein(s) involved in the type
shift.
Methodology/Principal Finding: Proteomic analysis identified one differentially expressed protein in the B. pertussis strains:
the type III cytotoxic effector protein BteA, which is responsible for host cell death in Bordetella bronchiseptica infections.
Immunoblot analysis confirmed the prominent expression of BteA protein in the nonvaccine-type strains but not in the
vaccine-type strains. Sequence analysis of the vaccine-type strains revealed an IS481 insertion in the 59 untranslated region
of bteA, 2136 bp upstream of the bteA start codon. A high level of bteA transcripts from the IS481 promoter was detected
in the vaccine-type strains, indicating that the transcript might be an untranslatable form. Furthermore, BteA mutant studies
demonstrated that BteA expression in the vaccine-type strains is down-regulated by the IS481 insertion.
Conclusion/Significance: The cytotoxic effector BteA protein is expressed at higher levels in B. pertussis nonvaccine-type
strains than in vaccine-type strains. This type-dependent expression is due to an insertion of IS481 in B. pertussis clinical
strains, suggesting that augmented expression of BteA protein might play a key role in the type shift of B. pertussis.
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Introduction
Bordetella pertussis is a human-specific pathogen that is the
etiologic agent of whooping cough, an acute respiratory disease
that is often particularly severe in infants [1]. Universal
immunization programs have contributed to a significant reduc-
tion in morbidity and mortality of pertussis, especially in infants
and children; however, the incidence of pertussis has increased in
several countries despite high vaccination coverage [2–5]. Since
the 1980s, a considerable genetic transition has been observed
between B. pertussis vaccine strains and circulating clinical strains in
many countries [6–11]. Genetic variations have been found in the
loci encoding the major B. pertussis virulence factors: pertussis toxin
S1 subunit (ptxA), pertactin (prn) and fimbriae 3 (fim3). Among
circulating B. pertussis strains, vaccine-type alleles (ptxA2, prn1 and
fim3A) have been replaced mainly with nonvaccine-type alleles
(ptxA1, prn2 and fim3B). It has been speculated that adaptation of
the bacterial population to vaccine-induced immunity has
produced this genetic shift, and is one possible explanation for
the resurgence of pertussis [12–15]. However, there have been few
reports of the exact mechanism underlying this phenomenon.
B. pertussis expresses various virulence factors, including adhesins
and toxins, which function to establish and maintain host infection.
Several virulence factors such as filamentous haemagglutinin (FHA)
and pertussis toxin (PT) are expressed under the control of the BvgAS
two-component regulatory system [1,16,17]. The BvgAS system also
positivelyregulates virulence factor secretion via the type III secretion
system (T3SS) [18,19]. T3SS is highly conserved among a number of
Gram-negative bacteria and functions as an injector of virulence
molecules (i.e., effectors) into the host cell through a needle-like
injection apparatus [20,21]. In B. pertussis, T3SS plays a role in
subverting the protective innate and adaptive immunity of the host.
Three T3SS-secreted proteins, BopN, BopD and Bsp22, have been
identified so far [22]. In the animal pathogen Bordetella bronchiseptica,
BopN is involved in the up-regulation of cytokine IL-10 [23], while
Bsp22polymerizestoformaflexiblefilamentousstructureatthetipof
the needle structure and associates with the pore component BopD
[24]. The Bsp22 translocon is expressed in a significant proportion of
B. pertussis clinical isolates but not in Tohama and Wellcome 28, the
common laboratory-adapted vaccine strains [22].
Genomic differences between B. pertussis clinical strains and the
vaccine strain Tohama have been investigated. The comparative
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17797genomics profiling revealed that the genome of B. pertussis Tohama
differs from clinical isolates in four regions (RD11 to RD14) [25].
In contrast, progressive gene loss mediated by homologous
recombination between IS481 insertion sequence elements has
been observed among recently circulating strains of B. pertussis
isolates [26,27]. IS481 is present in multiple copies on the B.
pertussis chromosome, and it plays a critical role in B. pertussis
evolution through genomic rearrangement.
Proteomic analysis has been widely applied to comparisons of
protein expression among different strains, and information accu-
mulated from genomic studies of Bordetellaspp. facilitates comparative
proteomic approaches to the investigation of B.pertussis clinical strains
[6,28]. In the present study, a proteomic approach was employed to
identify the protein(s) involved in the genetic shift from vaccine-type
to nonvaccine-type in B. pertussis strains. The protein profile analyses
identified one differentially expressed protein, the T3SS effector BteA
(alias BopC) [29,30], between the strain types. BteA is a 68 kDa
cytotoxic effector that has been identified in B. bronchiseptica but not in
the B. pertussis human pathogen. Here we studied the differential
expression of BteA protein in B. pertussis clinical strains and identified
a specific IS481 insertion in the 59 untranslated region (59-UTR) of
bteA in vaccine-type strains.
Results
Identification of BteA in B. pertussis nonvaccine-type
strain
A comparative proteomic analysis of two clinical strains was
performed to investigate the shift of B. pertussis strains from
vaccine-type to nonvaccine-type. Figure 1 shows 2-dimensional
electrophoretic (2-DE) maps of total protein expressed in the
nonvaccine-type clinical strain BP235 and the vaccine-type
BP233. Among .600 protein spots detected on the 2-DE gel,
one was notably absent in the 2-DE map of BP233. The protein
spot was observed in other nonvaccine-type strains (BP157,
BP159, BP162 and BP228), but not in other vaccine-type strains
(BP155, BP156, BP232 and BP243). The protein represented by
the spot was identified by LC-MS/MS analysis using tryptic
digests. The MS/MS of the protein digests provided four peptide
sequences (RPDEFAAR, FDALR, ITALNLR and
TQTQLLALQR) that matched the B. pertussis hypothetical
protein BP0500 (NCBI accession: NP_879352). Hypothetical
protein BP0500 was identified as the T3SS effector BteA, since
the sequence is highly conserved with 98% amino acid identity to
the BteA (BopC) of B. bronchiseptica [29,30].
High expression of BteA protein in nonvaccine-type
strains
Immunoblots of B. pertussis clinical strains using anti-BteA
antiserum detected high levels of a protein of ,68 kDa in all
nonvaccine-type clinical strains (BP157, BP159, BP162, BP228
and BP235), whereas BteA expression was greatly reduced in the
vaccine-type clinical strains (BP155, BP156, BP232, BP233 and
BP243). Additional products of .200 kDa were also detected in
the nonvaccine-type clinical strains. These high molecular mass
signals appear to be the protein bands that have been reported as a
multimeric complex of BteA in B. bronchiseptica [29,30] (see Figure
S1). T3SS function in the nonvaccine-type strains was confirmed
Figure 1. Comparative proteomic analysis of B. pertussis nonvaccine-type and vaccine-type strains. Total protein (10 mg) from the
nonvaccine-type and vaccine-type clinical strains was separated by 2-D gel electrophoresis and silver stained. The left upper panel shows the protein
profile of the nonvaccine-type BP235. The right upper panel shows the protein profile of the vaccine-type BP233. The red-boxed areas are enlarged
(lower panels). The arrow in left lower panel indicates the spot that was identified as type III effector BteA by LC-MS/MS analysis.
doi:10.1371/journal.pone.0017797.g001
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BteA chaperone) [29,31] and BopD (the T3SS translocon) [32].
BtcA and BopD polypeptides were detected in both strain types,
but the BtcA signals produced by the nonvaccine-type strains were
apparently lower than those of the vaccine-type strains (Figure 2).
The reason for the different expression is not clear. In contrast,
adenylate cyclase toxin (ACT), another Bordetella spp. virulence
factor, was detected at similar levels in both strain types.
In order to confirm BteA secretion by B. pertussis strains, BteA
polypeptide in the culture supernatants (CS) was subjected to
immunoblot analysis. BteA was detected in secreted proteins from
the nonvaccine-type clinical strain BP159 at 12, 24 and 48 h,
whereas the signal was very low in the vaccine-type clinical strain
BP155 over the 48-h time period (Figure 3). Conversely, signals
corresponding to PT-S1 subunit and FHA polypeptides were
detected in the supernatants of both cultures throughout the
sampling period, although silver staining revealed small differences
in their protein profiles after 24 h in culture.
Transcription of bteA
bteA gene expression in B. pertussis strains was investigated with
conventional RT-PCR and quantitative RT-PCR. bteA was
transcribed in both the nonvaccine-type (BP157, BP159, BP162,
BP228 and BP235) and vaccine-type (BP155, BP156, BP232,
BP233 and BP243) clinical strains (Figure 4A). Similarly, btcA
transcripts were detected in both strain groups. RT-PCR
experiments lacking reverse transcriptase showed no specific
product for bteA amplification, confirming negligible genomic
DNA contamination in the RNA preparations. Quantitative RT-
PCR (qRT-PCR) showed an average bteA transcript level of 0.146
(61SD range, 0.107 to 0.184) in nonvaccine-type strains and
0.095 (61SD range, 0.076 to 0.113) in vaccine-type clinical
strains, a difference that was not statistically significant (P=0.11)
(Figure 4B).
IS481 insertion in the bteA 59-UTR in vaccine-type strains
Sequencing of the bteA 59-UTR of the five vaccine-type strains
(BP155, BP156, BP232, BP233 and BP243), revealed a 1,043-bp
insertion sequence (IS481) 2136 bp upstream of the bteA start
codon (Figure 5A). IS481a, which is newly identified in B. pertussis,
showed 99% nucleotide sequence identity with IS481 of B. pertussis
Tohama. The CCTAAC sequence in the bteA 59-UTR is an
insertion site of IS481a and is duplicated by the insertion, although
the 6-bp consensus recognition sequence of IS481 has been
reported as NCTAGN [33]. IS481 insertions were not found in
the nonvaccine-type clinical strains, which had nucleotide
sequences that were 99% identical to that of B. pertussis Tohama.
In the bteA 59-UTR of the nonvaccine-type strains (BP157, BP159,
BP162 BP228 and BP235), one single nucleotide polymorphism
(ARG) was observed at 207 bp upstream of the bteA translation
start site (Figure 5B).
The bteA 59-UTR was PCR-amplified from chromosomal DNA
of other B. pertussis strains to confirm insertion of IS481. Among 61
vaccine-type clinical strains, 60 (98%) produced amplicons of
,3.1 kb, a size indicative of an IS481 insertion in the bteA 59-
UTR. One strain (BP121) had a product of ,2.1 kb, correspond-
ing to the predicted size of the native 59-UTR (data not shown). Of
the 23 nonvaccine-type strains examined, all generated ,2.1 kb
amplicons, confirming the absence of the IS481 insertion.
Determination of the bteA transcription start site
59-RACE mapping was used to identify the bteA transcription
start site in vaccine-type strain BP155. Nucleotide sequences of the
59-RACE PCR products revealed two transcription start sites, P1
and P2, located 268 and 2147 bp from the bteA translation start
codon (Figure 5A). The P1 start site (+1) was located within the
bteA 59-UTR, whereas the P2 start site (279) was located within
IS481a. Only the P1 start site was also found in the nonvaccine-
type strain BP159 (Figure 5B). IS481 contains an outward-facing
Figure 2. Expression of BteA, BtcA, BopD and ACT proteins in B. pertussis nonvaccine-type and vaccine-type strains. The nonvaccine-
type clinical strains (BP157, BP159, BP162, BP228 and BP235) and vaccine-type clinical strains (BP155, BP156, BP232, BP233 and BP243) were cultured
in modified SS medium for 18 h. Total protein extracted from bacterial cells was subjected to immunoblot analysis with anti-BteA, anti-BtcA, anti-
BopD or anti-ACT antiserum. For BteA detection, 10 mg of total protein was loaded in each lane.
doi:10.1371/journal.pone.0017797.g002
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flanking catalase gene (katA)i nB. pertussis [34]. However, the P2
start site is different from the katA transcription start site. The
transcription start site of btcA, also determined by 59-RACE, was
mapped to a T residue 31 bp upstream of the btcA translation start
codon in both the vaccine-type and nonvaccine-type strains
(Figure 5B).
Primer extension analysis was also performed in an attempt to
resolve the bteA transcription start sites. However, the start sites
could not be ascertained, probably due to low amounts of bteA
transcript in B. pertussis.
IS481a-promoter transcript is the major bteA transcript in
the vaccine-type strain
Expression of the IS481a-promoter transcript (P2 transcript) in
B. pertussis vaccine-type strain BP155 was analyzed by qRT-PCR
with TaqMan probes (Figure 5A). The P2 transcript and total bteA
(P1 + P2) transcripts were determined individually and the ratio of
P2 transcript to total bteA transcript was calculated. Based on four
independent experiments, the ratio (P2 transcript/P1 + P2
transcripts) was estimated to be 0.88 (61SD range, 0.70 to
1.09), indicating that the P2 transcript is the major bteA transcript
in the vaccine-type strain (data not shown).
BteA expression in B. pertussis BteA mutants
To clarify the effect of the IS481 insertion on BteA expression,
four BteA mutants (DbteA-BP155, DIS481-BP155, DbteA-BP157
and +IS481-BP157) were constructed from B. pertussis BP155
(vaccine-type) and BP157 (nonvaccine-type) by homologous
recombination (Figure 6A). The DbteA-BP155 and DbteA-BP157
mutants had a 178-bp deletion in the 59 region of bteA. In the
DIS481-BP155 mutant, a 2.2-kb insertion containing an intact bteA
59-UTR (derived from B. pertussis Tohama) replaced the native bteA
59-UTR + IS481a gene. In contrast, +IS481-BP157 mutant had a
3.2-kb insertion containing a bteA 59-UTR + IS481a (derived from
B. pertussis BP155) instead of its own bteA 59-UTR. Consequently,
DIS481-BP155 had an IS481a deletion from the bteA 59-UTR,
whereas the +IS481-BP157 mutant had an IS481a insertion in the
bteA 59-UTR. The btcA2bteA region of the mutants was verified by
DNA sequence analysis.
BteA expression in the bacterial cells and CS after 24 h in
culture was analyzed by immunoblot with anti-BteA antiserum
(Figure 6B). In DIS481-BP155 bacterial cells and CS, BteA
polypeptide(s) corresponding to ,68 kDa and .200 kDa were
detected at the same level as was observed in the BP157 wild-type
strain. In contrast, the signals of BteA polypeptide(s) from +IS481-
BP157 mutant were very low in both bacterial cells and CS.
Similarly, BteA polypeptide(s) were not detected in either DbteA-
BP155 or DbteA-BP157. These results clearly showed that BteA
protein expression is down-regulated by the IS481 insertion in B.
pertussis, and that the anti-BteA antiserum is highly specific to
BteA.
Discussion
The BteA effector (alias BopC) is required for the induction of
necrotic cell death during B. bronchiseptica infections, and is thought
to play a pivotal role in T3SS-mediated cell death [29,30,35].
BteA is also involved in dephosphorylation of tyrosine-phosphor-
ylated proteins (PY) of host cells [30], and its 130-amino acid N-
terminal sequence is associated with target lipid rafts [31]. BteA is
the only cytotoxic effector that has been identified in Bordetella spp.
In B. pertussis, low-passage clinical strains have an ability to express
a functionally active T3SS; however, BteA protein had not been
detected in the clinical and common laboratory-adapted strains by
MALDI-TOF mass spectrometry [22]. Here we demonstrate that
BteA protein is highly expressed in B. pertussis nonvaccine-type
Figure 3. BteA secretion from B. pertussis nonvaccine-type and vaccine type strains. Strains BP235 (nonvaccine-type) and BP233 (vaccine-
type) were cultured in modified SS medium, and the culture supernatants (CS) were collected at 12, 24 and 48 h. Protein samples prepared by
precipitation with 10% trichloroacetic acid were separated by 12.5% SDS-PAGE followed by silver staining (left panel). BteA, FHA and PT secretions
were analyzed by immunoblots using anti-BteA, anti-FHA or anti-PT antiserum (right panels). For BteA detection, the equivalent of 200 ml of CS was
loaded in each lane.
doi:10.1371/journal.pone.0017797.g003
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expression is down-regulated by IS481a insertion in the vaccine-
type strains. We provide the first evidence that BteA protein
expression is type-dependent due to the IS481a insertion in B.
pertussis clinical strains.
In Japan, B. pertussis circulating strains began to change from
vaccine-type to nonvaccine-type in the mid-1990s [8], and the
reported incidence of adult cases of pertussis has dramatically
increased since 2002 [36]. The genetic divergence in B. pertussis
circulating strains has also been observed in many other countries.
A possible explanation for the genetic divergence is that the type
shift is a result of vaccine-driven evolution [12–15]. More recently,
Mooi et al. [37] reported that expansion of B. pertussis strains with
increased PT production has contributed to the resurgence of
pertussis in the Netherlands. Here we showed prominent
expression of the T3SS effector protein BteA in the nonvaccine-
type strains, and that PT and ACT (important virulence factors of
B. pertussis) are expressed at the same level in both the nonvaccine
and vaccine-type strains. Besides vaccine-driven evolution, our
findings could provide another possible explanation for the type
shift from vaccine-type to nonvaccine-type, i.e., the augmented
expression of BteA protein in B. pertussis nonvaccine-type strains
may be involved in the type shift.
B. bronchiseptica BteA has in vitro cytotoxic activity against
cultured mammalian cells [18,22,29,30]. In this study, we
determined the cytotoxicity of B. pertussis BteA mutants by
measuring the release of lactate dehydrogenase (LDH) from L2
rat lung epithelial cells, J774 mouse macrophage-like cells, or
HeLa cells. However, even BteA-expressing strains (DIS481-
BP155 and wild-type BP157) showed low cytotoxicity (,10%),
and consequently no statistically significant differences in cytotox-
icity were observed among the wild-type and mutant strains. B.
pertussis is known to have a lower in vitro cytotoxicity than B.
bronchiseptica [18,22], which is consistent with the extremely low
secretion of BteA in B. pertussis as compared to B. bronchiseptica
(Figure S1). Therefore, a more sensitive and quantitative assay is
required to determine the BteA-dependent cytotoxicity of B.
pertussis.
Figure 4. RT-PCR analysis of bteA transcript in B. pertussis nonvaccine-type and vaccine-type strains. (A) RT-PCR with primers specific for
bteA and btcA. cDNA made from total RNA of nonvaccine-type (BP157, BP159, BP162, BP228 and BP235) and vaccine-type (BP155, BP156, BP232,
BP233 and BP243) clinical strains was used as templates for PCR. Genomic DNA (G) from B. pertussis strain Tohama was used as a positive control. A
mock reaction for bteA (2RT) consisted of reactions lacking reverse transcriptase. (B) Quantitative RT-PCR analysis of bteA transcript levels in the
nonvaccine-type and vaccine-type clinical strains listed in (A). The recA transcript was used as a reference. Each point represents one strain and
vertical bars indicate standard deviations.
doi:10.1371/journal.pone.0017797.g004
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238 copies of IS481 are present in the B. pertussis Tohama genome
[39]. In B. pertussis clinical strains, IS481 is also present in multiple
copies on the chromosome and it plays a critical role in B. pertussis
evolution [26,40]. Many IS elements have been shown to activate
the expression of neighboring genes. IS481 contains an outward-
facing promoter that is located in close proximity to the left
terminal inverted repeat, and this promoter is responsible for the
transcription of katA in certain B. pertussis strains [34]. Here we
identified an IS481a insertion in the bteA 59-UTR in B. pertussis
vaccine-type clinical strains and detected a high level of bteA
transcripts from the IS481a promoter (P2) compared with its own
promoter (P1). However, the vaccine-type strains showed a low
level of BteA protein expression, suggesting that insertion of
IS481a represses P1 promoter activity, and that P2 transcript has a
low translational efficiency from the additional nucleotide
sequence (79 nucleotides) at its 59 end. Use of a cell-free coupled
transcription-translation system revealed that the additional
nucleotide sequence is involved in down-regulation of transcrip-
tion and/or translation (Figure S2). The 59-UTR of bacterial
mRNAs can bear regulatory elements that are involved in down-
or up-regulation of translation [41]. The regulatory mechanisms in
this region are controlled by RNA-binding proteins, small
noncoding RNAs and structural rearrangements with the 59-
UTR. In addition, a 59 stem-loop structure that sequesters the
ribosomal binding site has been shown to be involved in
translational regulation. Bioinformatic analysis uncovered a
predicted stem-loop structure in the bteA 59-UTR of P2 transcript
(Figure S2).
In this study, the 59-UTRs of five B. pertussis vaccine-type clinical
strains were sequenced; all had an insertion of an IS481a in the
bteA 59-UTR, both transcribed in the same direction. In one of the
vaccine-type strains, BP155, the major bteA mRNA was tran-
scribed from P2 in the IS481a-promoter. These observations raise
the possibilities that (i) the P2 transcript is translated into BteA
under certain environmental conditions, and (ii) the P2 transcript
is translated into another novel protein by translational frame-
shifting. BteA is known to be regulated by the BvgAS system and
an extracytoplasmic function (ECF) sigma factor BtrS in B.
bronchiseptica [18,29]. In B. pertussis, it has been suggested that
expression of the T3SS translocon Bsp22 is blocked by post-
transcriptional regulation [18]. However, the molecular details of
the regulatory mechanism are still unclear. Further studies are
needed to determine the down-regulation of BteA protein in B.
pertussis vaccine-type clinical strains.
In conclusion, B. pertussis vaccine-type strains have been
replaced with the nonvaccine-type strains in many countries,
and the resurgence of pertussis has been observed in several
Figure 5. Physical maps of the btcA2bteA region of B. pertussis vaccine-type and nonvaccine-type strains. (A) The vaccine-type clinical
strain BP155. The location of IS481a is represented by a gray arrow on the physical map. The recognition sequence of IS481a is underlined. The two
mapped transcriptional start sites (P1 and P2) of bteA are shown by arrows. Region amplified by qRT-PCR to determine the IS481a-promoter (P2) and
total (P1 + P2) transcripts are shown by two-headed arrows below the physical map. (B) The nonvaccine-type clinical strain BP159. The mapped
transcriptional start sites of bteA (P1) and btcA [P (btcA)] are shown by arrows. The single nucleotide polymorphism (ARG) at 2207 bp from the bteA
translation start codon is indicated by an asterisk.
doi:10.1371/journal.pone.0017797.g005
Differential Expression of BteA in B. Pertussis
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17797nations. In Japanese B. pertussis clinical strains, the T3SS effector
BteA is highly expressed in nonvaccine-type strains as compared
with the vaccine-type strains. Our findings indicate that augment-
ed expression of BteA protein in B. pertussis circulating strains could
play a key role in the type shift. However, it is unclear whether
BteA protein is implicated in the resurgence of pertussis. Further
studies are needed to determine the expression of BteA protein in
B. pertussis circulating strains on a global scale.
Materials and Methods
Bacterial strains and growth conditions
B. pertussis clinical strains were selected from the laboratory
collection of the National Institute of Infectious Diseases, Tokyo,
Japan. The selection criteria included the time and geographic
location of isolation, and their ptxA and prn alleles. A total of 10
clinical strains from 2002 to 2004 in Japan were included. Of the
10 clinical strains, 5 harbored ptxA1 and prn2 alleles (BP157,
BP159, BP162, BP228 and BP235; nonvaccine-type strains), while
the others carried ptxA2 and prn1 (BP155, BP156, BP232, BP233
and BP243; vaccine-type strains). All strains were cultured on
Bordet-Gengou agar (BG agar, Difco) supplemented with 1%
glycerol and 15% defibrinated horse blood or in modified Stainer-
Scholte (SS) medium [42].
Two-dimensional gel electrophoresis (2D-PAGE)
2D-PAGE was performed based on the O’Farrell method [43]
with minor modifications. B. pertussis clinical strains grown on BG
agar plates were resuspended in casamino acid solution (1%
casamino acid, 0.6% NaCl, pH 7.1). Bacterial cells were precipi-
tated by centrifugation (12,000 6 g, 10 min) and resuspended in
SDS-lysis buffer (62.5 mM Tris-HCl, 1% SDS, 10% glycerol, 5%
2-mercaptoethanol, pH 6.8) by sonication. Total protein was
extracted by boiling for 3 min, followed by centrifugation. A
portion (10 mg, approximately 2 ml) of the protein solution was
mixed with 20 ml of sample buffer [8.5 M urea, 2% Nonidet P-40,
2% Ampholine (pH 3.5 to 10)], and applied to an isoelectric
focusing tube gel (2.0 mm inside diameter by 12.0 cm) containing
4% polyacrylamide, 8.5 M urea, 2% Nonidet P-40, and 2%
Ampholine (pH 5 to 7 and pH 3.5 to 10 in a ratio of 1:4). Proteins
werefocusedat10uCfor17 h(1 hat200 V,2 hat400 V,and14 h
at 800 V) with 10 mM H3PO4 (anolyte) and 20 mM NaOH
(catholyte).In the second dimension, the electrofocused tubegel was
electrophoresed in 12% SDS-PAGE. The separated polypeptides
were visualized by silver staining and analyzed with the PDQuest
2-D Analysis Software (Bio-Rad, Hercules, CA). The Lowry assay
was used to measure protein concentrations in a trichloroacetic acid
(TCA) pellet (resuspended in 1 N NaOH) using bovine serum
albumin as a standard.
Protein identification
2D-PAGE gels were stained with silver nitrate without
glutaraldehyde fixation [44], and protein spots of interest were
excised. Proteins were reduced with 10 mM DTT, alkylated with
55 mM iodoacetamide, and digested with sequencing grade-
modified trypsin (Promega, Madison, WI). Digested peptides were
separated on a C18 capillary column (0.2 by 50 mm, Michrom
Bioresources, CA) equipped with a Chorus 220 solvent delivery
system and an HTC PAL auto-sampler system (CTC Analytics
AG, Zwingen, Switzerland). Separated peptides were analyzed by
the Finnigan LCQ
TM Deca XP ion trap mass spectrometer
(Thermo Fisher Scientific Inc., MA) with electrospray ionization
(ESI) interface using the Nanosprayer FS (GL Sciences Inc.,
Japan). To identify peptides, data files were generated from the
MS/MS scans by Bioworks 3.0 using the SEQUEST algorithm
(threshold, 10
5; minimum group scan 2, Xc .1.0, Thermo Fisher
Scientific) and searched against the complete amino acid database
derived from the B. pertussis Tohama genome database.
Figure 6. Construction and characterization of B. pertussis BteA mutants. (A) Physical map of the btcA2bteA region of BteA mutants derived
from B. pertussis BP155 (vaccine-type) and BP157 (nonvaccine-type). WT, wild-type; DbteA, a 178-bp deletion around the 59 region of bteA; DIS481,
IS481a deletion from the bteA 59-UTR; +IS481,I S 481a insertion in the bteA 59-UTR. (B) Expression of BteA protein in the BteA mutants. The mutants
were cultured in modified SS medium for 24 h. Total protein from the bacterial cells (Cell) and culture supernatants (CS) was analyzed with
immunoblot using anti-BteA antiserum.
doi:10.1371/journal.pone.0017797.g006
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and ACT
The BteA gene (NCBI accession: NP_879352) was amplified by
PCR from B. pertussis Tohama DNA using BteA-F and BteA-R
primers, and cloned into the XmnI/HindIII sites of pMal-c2X
(New England Biolabs, Beverly, MA) to generate a maltose
binding protein (MBP) fusion with BteA. Production of this fusion
protein was induced in E. coli BL21 with 0.5 mM isopropyl-b-D-
thiogalactopyranoside (IPTG) and subsequently purified using
amylose resin (New England Biolabs) and Resource Q (Amersham
Pharmacia Biotech, Uppsala, Sweden) columns. A two-step PCR
was carried out to amplify recombinant BtcA (NCBI accession:
NP_879351). The first PCR was performed using the BtcA-BteA-
F3 and BtcA-BteA-R3 primers (Table S1), which amplified the
region between positions 165122 and 167190 of the B. pertussis
Tohama genome (GenBank accession: BX640412). In the second
PCR, btcA was amplified from the first PCR product with the 5-
BtcA and 3-BtcA primers (Table S1) and cloned into the NdeI/
HindIII sites of pCold II DNA (TAKARA Bio Inc.). His-tagged
BtcA was induced in E. coli BL21 with 0.5 mM IPTG at 15uC and
purified using the HisTrap FF Crude Kit (GE Healthcare UK
Ltd.). A recombinant catalytic domain of B. pertussis adenylate
cyclase toxin (ACT) was a gift from Mineo Watanabe.
Antibodies against MBP-BteA, BtcA and ACT were generated
in mice at Nippon Biotest Laboratories, Inc. (Tokyo, Japan). The
MBP-BteA antiserum was pre-absorbed with MBP2 protein (New
England BioLabs) and the resulting antiserum was used.
Immunoblot analysis
B. pertussis clinical strains were inoculated in modified SS
medium with a starting optical density of 0.2 at 600 nm, and
further cultured with shaking at 36uC. Total protein was extracted
with SDS-lysis buffer, and culture supernatant (CS) proteins were
precipitated with 10% TCA. Protein samples were subjected to
SDS-PAGE, transferred to nitrocellulose membranes (Bio-Rad)
and incubated with anti-BteA, anti-BtcA, anti-BopD [32], anti-
ACT, anti-FHA, or anti-PT antiserum. Antigen-antibody com-
plexes were visualized using horseradish peroxidase (HRP)-
conjugated secondary antibody (Bio-Rad, Hercules, CA) and
ECL Western Blotting Detection Reagents (GE Healthcare).
DNA sequencing
The region between the btcA and bteA gene corresponding to
positions 165122 to 168021 of B. pertussis Tohama (GenBank
accession: BX640412) was amplified in vaccine-type and non-
vaccine-type clinical strains with the appropriate primers and
sequenced. Sequencing reactions were carried out with the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA), and the products were sequenced on an ABI
PRISM 3130xl Genetic Analyzer (Applied Biosystems).
Transcriptional analyses
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN,
Hilden, Germany) and treated with RNase-free DNase (Promega)
to degrade contaminating DNA. Reverse transcriptase-PCR (RT-
PCR) was performed with bteA RT-R and btcA RT-R primers
(Table S1) using the TAKARA One Step RNA PCR Kit (AMV,
TAKARA Bio Inc.). PCR was performed with the following
conditions: one cycle of 50uC for 30 min, 95uC for 2 min; 25
cycles of 95uC for 30 s, 58uC for 30 s, 72uC for 1 min; and a final
incubation at 72uC for 10 min. Primer sets, bteA RT-F/bteA RT-
R and btcA RT-F/btcA RT-R, were used for bteA and btcA
amplification, respectively (Table S1). Products were analyzed by
electrophoresis on a 1.5% agarose gel. Reverse transcriptase was
omitted from the negative control reaction mixtures.
For quantitative RT-PCR (qRT-PCR), 5 mg of RNA was
reverse transcribed into cDNA using the SuperScript First-Strand
Synthesis System (Invitrogen, Carlsbad, CA) with random
hexamer primers. Relative levels of total bteA and recA transcripts
were determined using TaqMan probes (bteA- and recA-probes,
Table S1) and Premix Ex TaqTM (Perfect Real Time, TAKARA
Bio Inc.) with the ABI PRISM 7500 Sequence Detection System
(Applied Biosystems). The qRT-PCR conditions were 30 s at
95uC, followed by 40 cycles of 95uC for 15 s and 60uC for 1 min.
The expression of recA was used as an internal control [45]. All
samples were run in triplicate and bteA transcript (P1 + P2
transcripts) was normalized to the recA transcript for each sample.
The bteA IS481a-promoter transcript (P2 transcript) was deter-
mined using a TaqMan probe (IS481-bteA probe). The qRT-PCR
conditions were 30 s at 95uC, followed by 40 cycles of 95uC for
15 s and 55uC for 1 min. The ratio of P2 transcript to total bteA
transcript (P2 transcript/P1 + P2 transcripts) was estimated from
four independent experiments. The regions amplified by qRT-
PCR are shown in Figure 6A.
Mapping transcriptional start sites
59 rapid amplification of cDNA ends (59-RACE) was performed
using 59-Full RACE Core Set (TAKARA Bio Inc.) according to
the manufacturer’s instructions. Reverse transcription was execut-
ed at 55uC using a 59 phosphorylated RT primer (bteA-RT, Table
S1). The first PCR used primers bteA-S1 (S1) and bteA-A1 (A1)
primers, and bteA-S2 (S2) and bteA-A2 (A2) for the second (Table
S1). PCR products were cloned into the pT7Blue T-vector
(Novagen, Madison, Wis.) and transformed into E. coli XL1-Blue,
which were plated on LB agar plates. Several clones were
sequenced. The transcription start site of btcA was located using 59-
RACE with five primers, btcA-RT (59 phosphorylated primer),
btcA-S1 (S1), btcA-A1 (A1), btcA-S2 (S2) and btcA-A2 (A2) (Table
S1).
Generation of BteA mutants
Four BteA mutants, DbteA-BP155, DbteA-BP157, DIS481-BP155
and +IS1481-BP157, were constructed by homologous recombi-
nation as described previously with minor modifications [30]
(Figure 6A).
BteA-deficient mutants: A 2.2-kbp DNA fragment containing a 59
portion of the bteA gene was amplified by PCR with the B1-bteA
and B2-bteA primers (Table S1) using the B. pertussis Tohama
genomic DNA as the template. The PCR product was cloned into
the pDONR221 vector (Invitrogen) to obtain pDONR-bteA by
means of adaptor PCR and site-specific recombination techniques
with the Gateway Cloning System (Invitrogen). Inverse PCR was
then carried out with R1-bteA and R2-bteA primers (Table S1)
using circular pDONR-bteA as the template. The R1-bteA and
R2-bteA primers contained a BamHI site. The resulting PCR
product was digested with BamHI and self-ligated to obtain
pDONR-DbteA, which contained a 178-bp deletion around the 59
region of bteA. pDONR-DbteA was mixed with pABB-CRS2 [46]
to obtain pABB-DbteA using the Gateway Cloning System. pABB-
DbteA was then introduced into E. coli SM10lpir and transconju-
gated into streptomycin (SM)-resistant B. pertussis BP155 (vaccine-
type) and BP157 (nonvaccine-type) clinical strains. The resultant
mutant strains were designated DbteA-BP155 and DbteA-BP157.
IS481-deletion mutant: pABB-bteA was constructed from pDONR-
bteA. pABB-bteA was introduced into E. coli SM10lpir and
transconjugated into SM-resistant B. pertussis vaccine-type BP155.
The resultant mutant strain was designated DIS481-BP155.
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containing the bteA 59-UTR and IS481a was amplified with the
B1-bteA and B2-bteA primers (Table S1) using B. pertussis BP155
genomic DNA as the template. pABB-bteA+IS481 was constructed
from pDONR-bteA+IS481 and transconjugated into SM-resistant
B. pertussis nonvaccine-type BP157 via E. coli SM10lpir. The
resultant mutant strain was designated +IS481-BP157.
Statistical analysis
The Student’s t-test was employed. A value of P,0.05 was
considered statistically significant.
Nucleotide sequence accession number
The IS481a sequence was deposited in the DDBJ/EMBL/
GenBank nucleotide sequence databases under accession number
AB473880.
Supporting Information
Figure S1 High secretion of BteA protein in Bordetella
bronchiseptica. B. bronchiseptica (BB R05), B. pertussis BP155
(vaccine-type) and BP157 (nonvaccine-type) were cultured in
modified SS medium for 24 h. Total protein extracted from the
bacterial cells (Cell) and culture supernatants (CS) was separated
by SDS-PAGE followed by silver staining (left panel). Immuno-
blots were incubated with anti-BteA, anti-BtcA or anti-BopD
antiserum (right panel). For BteA detection, 0.5 mg of total protein
(for Cell) and 5 ml of CS were loaded in the indicated lanes. The
amount of total protein loaded was one-twentieth of that in
Figure 2, and the loaded CS volume was one-fortieth of that in
Figure 3.
(TIF)
Figure S2 In vitro transcription-translation analysis of
a bteA 59-UTR deletion series. (A) bteA 59-UTR deletion genes
were PCR-amplified using B. pertussis BP155 (vaccine-type) as the
template. Proteins were synthesized using the WakoPURE System
(Wako Pure Chemical Industries, Ltd.). The 59-UTR deletion
genes harbored the T7 promoter at their 59 end. (B) Expression of
BteA protein in an in vitro transcription-translation system
(WakoPURE System). The synthesized product was analyzed
with immunoblots using anti-BteA antiserum. NC, negative
control. (C) A predicted stem-loop structure in the 59-UTR of
bteA mRNA (P2 transcript). The RNA secondary structure was
analyzed by CentroidFold (http://www.ncrna.org/centroidfold).
The schematic shows a simplified map. TIR, translation initiation
region.
(TIF)
Table S1 Primers and probes in this study.
(XLS)
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